Company profile
Ticker
DRMA, DRMAW
Exchange
Website
CEO
Mr. Gerald T. Proehl
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Meat-Tech 3D Ltd., MeaTech 3D Ltd.
SEC CIK
DRMA stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
6 Feb 25
424B3
Prospectus supplement
5 Feb 25
D/A
$2.55 mm in equity / options / securities to be acquired, sold $2.55 mm, 8 investors
4 Feb 25
S-3
Shelf registration
30 Jan 25
D
$2.55 mm in equity / options / securities to be acquired, sold $2.55 mm, 7 investors
28 Jan 25
8-K
Dermata Therapeutics Announces $2.55 Million Private Placement
23 Jan 25
8-K
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari™ with Daxxify
21 Jan 25
8-K
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
13 Nov 24
10-Q
2024 Q3
Quarterly report
13 Nov 24
D
$3.50 mm in options / securities to be acquired, sold $3.50 mm, 1 investor
27 Sep 24
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 25
SC 13D/A
PROEHL GERALD T
13 Feb 25
SC 13G
INTRACOASTAL CAPITAL, LLC
28 Jan 25
SC 13D/A
PROEHL GERALD T
23 Jan 25
4
MARY FISHER
23 Jan 25
4
Hoose Kyri K. Van
23 Jan 25
4
GERALD T PROEHL
23 Jan 25
4
DAVID F HALE
23 Jan 25
4
Andrew Seth Sandler
14 Jan 25
4
Christopher J. Nardo
14 Jan 25
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 6.14 mm | 6.14 mm | 6.14 mm | 6.14 mm | 6.14 mm | 6.14 mm |
Cash burn (monthly) | (no burn) | 191.23 k | 1.08 mm | 845.10 k | 1.14 mm | 528.16 k |
Cash used (since last report) | n/a | 907.34 k | 5.10 mm | 4.01 mm | 5.41 mm | 2.51 mm |
Cash remaining | n/a | 5.24 mm | 1.04 mm | 2.13 mm | 736.50 k | 3.64 mm |
Runway (months of cash) | n/a | 27.4 | 1.0 | 2.5 | 0.6 | 6.9 |
Institutional ownership, Q3 2024
6.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 4.01 mm |
Total shares | 362.83 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Proehl Gerald T | 183.35 k | $292.00 k |
Intracoastal Capital | 143.94 k | $311.00 k |
Hale David F | 33.50 k | $53.00 k |
WFC Wells Fargo & Company | 2.05 k | $3.35 mm |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jan 25 | Hale David F | Common Stock | Grant | Acquire A | Yes | No | 0 | 78,741 | 0.00 | 80,957 |
21 Jan 25 | Proehl Gerald T | Common Stock | Grant | Acquire A | Yes | No | 0 | 787,402 | 0.00 | 799,508 |
21 Jan 25 | Proehl Gerald T | Warrant Common Stock | Grant | Acquire A | Yes | No | 1.27 | 787,402 | 1.00 mm | 787,402 |
21 Jan 25 | Hale David F | Warrant Common Stock | Grant | Acquire A | Yes | No | 1.27 | 78,741 | 100.00 k | 78,741 |
21 Jan 25 | Hoose Kyri K. Van | Common Stock | Grant | Acquire A | No | No | 0 | 78,741 | 0.00 | 78,741 |
21 Jan 25 | Hoose Kyri K. Van | Warrant Common Stock | Grant | Acquire A | No | No | 1.27 | 78,741 | 100.00 k | 78,741 |
21 Jan 25 | Fisher Mary | Common Stock | Grant | Acquire A | No | No | 0 | 196,851 | 0.00 | 196,946 |
21 Jan 25 | Fisher Mary | Warrant Common Stock | Grant | Acquire A | No | No | 1.27 | 196,851 | 250.00 k | 196,851 |
13 Jan 25 | Brittany Bradrick | Stock Option Common Stock | Grant | Acquire A | No | No | 1.38 | 5,000 | 6.90 k | 5,000 |
News
Dermata Therapeutics To Be Issued US Patent titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS".
3w ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
4w ago
Dermata Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS (INCLUDING ACNE)".
2mo ago
Press releases
Dermata to Present on BioPub on January 31, 2025
3w ago
Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment
3w ago
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
4w ago
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
4w ago
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
1mo ago